CSG's Ukraine Joint Ventures Promise Growth, but Governance Questions Keep the Stock Under Fire

Czech defence group CSG plans Ukraine joint ventures for artillery production, but faces a NATO ban, shareholder dispute, and expiring EU financing window.

The Czechoslovak Group is doubling down on the front lines. Chairman Michal Strnad announced on 13 May that the Czech defence conglomerate will invest several million euros in joint ventures inside Ukraine, focused on artillery ammunition production, spare parts for armoured vehicles, and speciality steel for plating. The plan aims to bring manufacturing closer to the battlefield, where supply speed is often more critical than unit cost. CSG's medium-term target is to produce 1.1 million large-calibre rounds per year, up from roughly 630,000 last year.

Yet the operational logic of the Ukraine expansion is running headlong into a wall of market scepticism. CSG shares closed at €16.05 on the day of Strnad’s announcement, a 0.43% gain on the session but still more than 52% below the January high reached shortly after the Amsterdam IPO priced at €25.00. The stock has slumped 23.38% over the past month and trades about 31% below its 50-day moving average. The annualised 30-day volatility is elevated, signalling that investors see risks far beyond the factory floor.

Those risks crystallise in three unresolved cases. The most immediate is a NATO ban. The alliance’s procurement agency, NSPA, placed CSG’s Spanish subsidiary Fábrica de Municiones de Granada on a suspension list in July 2025, initially for four months but later extended indefinitely. At the time FMG held at least three active contracts for tank artillery. Crucially, the ban did not appear in the 728-page IPO prospectus published just before the January listing. EU rules can require disclosure of even potential investigations if they are material to investors. CSG insists it conducted a thorough legal review and found no evidence of irregularities or unlawful conduct, adding that FMG can still sell directly to individual NATO states. The company says it expects no material impact on its business or financial position.

The second headache is a dispute with minority shareholder Petr Kratochvíl. According to Czech media reports, Kratochvíl exercised a put option shortly before the IPO, demanding roughly €1.4 billion for his 10% stake in CSG Land Systems, a business line where he also holds blocking rights. CSG counters that external legal advisers concluded the put was not validly exercised, and therefore no actual or contingent liability needed to be disclosed in the audited financial statements. Separately, the group disclosed that a €275 million claim from the pre-IPO sale of non-core assets was fully settled in the first quarter of 2026.

The third challenge is a ticking clock on cheap financing. A Slovak munitions framework agreement with a maximum volume of €58 billion can be funded through the EU’s SAFE programme at an interest rate of just 1% — but only if at least two member states participate. That window closes at the end of May 2026. So far no partner has confirmed involvement; Romania has denied ministerial-level talks, while Croatia is still weighing participation.

None of this has dented analyst confidence in the underlying business. Moody’s recently upgraded CSG to investment grade. JPMorgan has a price target of €40, and the consensus of nine analysts sits at €35.40 — more than double the current share price. The numbers back them up: revenue surged 71.7% last year to €6.7 billion, net profit reached €872 million, and management guides for 2026 sales between €7.4 billion and €7.6 billion with an adjusted EBIT margin of 24-25%.

New orders continue to flow. At the end of April, CSG secured a West European contract for 155mm artillery ammunition valued at nearly €250 million. Excalibur International, a CSG subsidiary, also won Southeast Asian orders worth around €2.5 billion. The planned acquisition of a 49% stake in Hirtenberger Defence Systems awaits regulatory clearance.

That leaves the upcoming quarterly report on 20 May as the pivotal moment. The market will focus not on fresh headlines but on execution: how much of the roughly €14 billion order backlog is converting into revenue, what one-off costs the IPO generated, and whether management can credibly address the lingering governance questions. For now, the stock remains pinned near its lows, caught between an aggressive expansion strategy and the trust deficit that has cut its value in half.